OS Therapies announced upcoming participation in major healthcare conferences and provided an update on its OST-HER2 immunotherapy for metastatic osteosarcoma. The company expects key regulatory meetings with the FDA, MHRA, and EMA in September 2026, followed by Biologics License Application (BLA) submissions and conditional marketing authorization requests in Q4 2026. OST-HER2 has received multiple designations including Orphan Drug and Fast Track, and positive Phase 2b data supports its potential for early market access in 2027. OS Therapies also plans to advance its animal health program and next-generation antibody drug conjugates.
Nvidia has returned a record $26 billion to its shareholders after increasing its dividend by an extraordinary 2,400%. This massive payout highlights the company's strong financial position and commitment to rewarding investors. The significant divid...
AGCO introduced the Massey Ferguson N-Series split/narrow row planters at the 2026 Farm Progress Show, featuring factory-installed Precision Planting technology and modular design. These planters come in six configurations, offering farmers flexibili...
In August 2026, US private-sector employment grew by 38,000 jobs, marking the slowest job creation pace since January. Base pay increased by 3.2% and gross pay by 4.7% year-over-year, with job-changers seeing higher wage growth than job-stayers. The ...
Oxford BioMedica's shares fell 15% after Novartis and Bristol Myers Squibb paused enrollment in their autoimmune CAR-T therapy trials due to safety concerns, including patient deaths and inflammatory events. Despite this, broker Panmure Liberum maint...
Goldman Sachs analyzed $10 trillion in equity holdings and found that both hedge funds and mutual funds share strong interest in four large-cap dividend-paying financial stocks: Bank of America, Capital One Financial, Mastercard, and Visa. These comp...
